Finn Laura, Tan Winston
Hematology/Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
ISRN Oncol. 2012;2012:478607. doi: 10.5402/2012/478607. Epub 2012 Jun 3.
No single therapy benefits the majority of patients in the practice of oncology as responses differ even among patients with similar tumor types. The variety of response to therapy witnessed while treating our patients supports the concept of personalized medicine using patients' genomic and biologic information and their clinical characteristics to make informed decisions about their treatment. Personalized medicine relies on identification and confirmation of biologic targets and development of agents to target them. These targeted agents tend to focus on subsets of patients and provide improved clinical outcomes. The continued success of personalized medicine will depend on the expedited development of new agents from proof of concept to confirmation of clinical efficacy.
在肿瘤学实践中，没有单一疗法能使大多数患者受益，因为即使是肿瘤类型相似的患者，其反应也存在差异。在治疗患者过程中所见到的对治疗反应的多样性，支持了使用患者的基因组和生物学信息及其临床特征来做出关于其治疗的明智决策的个性化医疗概念。个性化医疗依赖于生物靶点的识别与确认以及针对这些靶点的药物研发。这些靶向药物往往针对特定患者亚群，并能改善临床疗效。个性化医疗的持续成功将取决于从概念验证到临床疗效确认的新型药物的加速研发。
